Needham & Company issued a buy rating, and Leerink Partners began coverage of Collegium Pharmaceutical, Inc. on September 23, 2026.
2 reports, 1 independent
Updated Sat 00:00
No new developments lately
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Needham & Company issued a buy rating, and Leerink Partners began coverage of Collegium Pharmaceutical, Inc. on September 23, 2026.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Needham & Company
American independent investment bank and asset management firm
-
Leerink partners
U.S. investment bank
Related events
- Leerink Partners started coverage on ANI Pharmaceuticals shares.
- Leerink partners, TD Cowen, and William Blair initiated coverage and set ratings for Kailera Therapeutics.
- Citigroup reissued a market outperform rating and Needham lifted its target price for Alkami Technology Inc.
- Leerink Partners provided coverage and price targets for Freenome on September 26, 2026.
- Needham & Company provided analyst coverage for TechTarget stock on September 24, 2026.